Hydroxyurea Proven Safe and Effective for Pediatric Sickle Cell Disease

Emory University researchers have confirmed that hydroxyurea, a widely used oral chemotherapy drug, remains a safe and effective long-term treatment for children with sickle cell disease (SCD). A study tracking over 2,100 pediatric patients found that those on hydroxyurea had fewer ER visits and hospitalizations compared to untreated peers, with benefits sustained over an average of five years.

Hydroxyurea, manufactured by Bristol Myers Squibb, Medisca, and Teva Pharmaceuticals USA, Inc., helps prevent sickle-shaped red blood cells from forming, reducing pain crises, anemia, and lung complications. Despite initial concerns due to its chemotherapy origins, the study reaffirms its safety and accessibility, critical for families who may lack access to newer, high-cost therapies like gene editing.

At OxyDial, we recognize hydroxyurea as a cornerstone of SCD management, especially in underserved communities. This study underscores the importance of reliable, affordable treatments in improving daily outcomes for pediatric patients.